Dongfang Biotech

China - BeijingBiotechnology1 H-1B visas (FY2023)

Focus: Dongfang Biotech is a China-based biotechnology company specializing in antibody therapies. Limited public data restricts assessment of market position and scale.

Metabolic Diseases Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Dongfang Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Dongfang Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

JY09

Healthy

Phase 1

Clinical Trials (1)

NCT02971722a Study of JY09 in Chinese Healthy Subjects

Phase 1

Help build intelligence for Dongfang Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work in antibody therapeutics, a high-growth modality with significant unmet needs in Asian markets
Potential early-stage equity upside if company achieves clinical or commercial milestones
Chance to contribute to a pure-play biotech focused on a single, well-defined therapeutic area

Watch Out For

No active job openings and minimal public hiring signals suggest limited near-term career mobility or expansion
No disclosed pipeline, clinical trials, products, revenue, or financial data creates visibility risk and inability to assess company trajectory
Single H1B approval in 2023 with no denials suggests minimal international hiring infrastructure for visa sponsorship

Generated by Claude from Dongfang Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Exendin-4 Fc fusion protein

Diabetes Mellitus, Type 2

Phase 1

Clinical Trials (1)

NCT06247748Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

Phase 1

JY09

Diabetes Mellitus, Type 2

Phase 1

Clinical Trials (1)

NCT04354090Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09

Phase 1

Recombinant anti-VEGFR2 fully human monoclonal antibody

NSCLC

Phase 2/3

Clinical Trials (1)

NCT04874844JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Phase 2/3

Exendin-4 Fc fusion protein injection

Type 2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT06254014A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Phase 3

Exendin-4 Fc fusion protein injection

Type2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT06257966A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Metabolic Diseases, Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Metabolic Diseases

4 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub